Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All curcumin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchCurcuminCurcumin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 82% Improvement Relative Risk Mortality (b) 60% Mortality (c) 91% Mortality (d) 67% Curcumin  Pawar et al.  EARLY TREATMENT  DB RCT Is early treatment with curcumin beneficial for COVID-19? Double-blind RCT 140 patients in India (July - September 2020) Trial compares with probiotics, results vs. placebo may differ Lower mortality with curcumin (p=0.017) c19early.org Pawar et al., Frontiers in Pharmacology, May 2021 Favors curcumin Favors probiotics

Oral Curcumin With Piperine as Adjuvant Therapy for the Treatment of COVID-19: A Randomized Clinical Trial

Pawar et al., Frontiers in Pharmacology, doi:10.3389/fphar.2021.669362, CTRI/2020/05/025482
May 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Curcumin for COVID-19
15th treatment shown to reduce risk in February 2021
 
*, now known with p = 0.000000046 from 26 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,900+ studies for 60+ treatments. c19early.org
RCT 140 patients, 70 treated with curcumin and piperine (for absorption), and 70 treated with probiotics, showing faster recovery, lower progression, and lower mortality with curcumin.
This is the 3rd of 20 COVID-19 RCTs for curcumin, which collectively show efficacy with p=0.0000093.
This is the 6th of 26 COVID-19 controlled studies for curcumin, which collectively show efficacy with p=0.000000046 (1 in 22 million).
risk of death, 81.8% lower, RR 0.18, p = 0.02, treatment 2 of 70 (2.9%), control 11 of 70 (15.7%), NNT 7.8.
risk of death, 60.0% lower, RR 0.40, p = 0.39, treatment 2 of 15 (13.3%), control 5 of 15 (33.3%), NNT 5.0, severe group.
risk of death, 90.9% lower, RR 0.09, p = 0.05, treatment 0 of 25 (0.0%), control 5 of 25 (20.0%), NNT 5.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), moderate group.
risk of death, 66.7% lower, RR 0.33, p = 1.00, treatment 0 of 30 (0.0%), control 1 of 30 (3.3%), NNT 30, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), mild group.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Pawar et al., 28 May 2021, Double Blind Randomized Controlled Trial, India, peer-reviewed, 8 authors, study period July 2020 - September 2020, this trial compares with another treatment - results may be better when compared to placebo, trial CTRI/2020/05/025482.
This PaperCurcuminAll
Oral Curcumin With Piperine as Adjuvant Therapy for the Treatment of COVID-19: A Randomized Clinical Trial
Kirti S Pawar, Rahul N Mastud, Satheesh K Pawar, Samragni S Pawar, Rahul R Bhoite, Ramesh R Bhoite, Meenal V Kulkarni, Aditi R Deshpande
Frontiers in Pharmacology, doi:10.3389/fphar.2021.669362
Background: Coronavirus disease-2019 (COVID-19) has a wide range of pathophysiological effects. Curcumin, an active constituent of Curcuma longa (turmeric), has several properties, including anti-inflammatory, antioxidant, antiviral, antithrombotic, and anti-proliferative effects, which make it a promising candidate for the symptomatic treatment of COVID-19. Objective: We aimed to determine the effects of curcumin administered with piperine (to optimize absorption) on symptoms in patients with COVID-19 in a double-blind, randomized, controlled trial at a 30-bed dedicated COVID Health Center (DCHC) in Maharashtra, India. Methods: In addition to conventional COVID-19 treatment, patients in the control group received a dose of probiotics twice a day, and patients in the study group received curcumin (525 mg) with piperine (2.5 mg) in tablet form twice a day. The effects of curcumin/piperine treatment on primary and secondary outcomes were assessed for the duration of hospitalization. Results: Patients with mild, moderate, and severe symptoms who received curcumin/ piperine treatment showed early symptomatic recovery (fever, cough, sore throat, and breathlessness), less deterioration, fewer red flag signs, better ability to maintain oxygen saturation above 94% on room air, and better clinical outcomes compared to patients of the control group. Furthermore, curcumin/piperine treatment appeared to reduce the duration of hospitalization in patients with moderate to severe symptoms, and fewer deaths were observed in the curcumin/piperine treatment group. Conclusions: Administration of oral curcumin with piperine as an adjuvant symptomatic therapy in COVID-19 treatment could substantially reduce morbidity and mortality, and ease the logistical and supply-related burdens on the healthcare system. Curcumin could be a safe and natural therapeutic option to prevent Post-Covid thromboembolic events.
ETHICS STATEMENT The studies involving human participants were reviewed and approved by The Royal Pune Independent Ethics Committee. The patients/participants provided their written informed consent to participate in this study. AUTHOR CONTRIBUTIONS KP contributed to study design, data interpretation, writing of the manuscript, and literature search; RM, SKP, and SSP contributed to data collection and literature search. RhB and RmB performed the literature search; and MK and AD performed the data analysis. SUPPLEMENTARY MATERIAL The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2021.669362/ full#supplementary-material Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
Aggarwal, Harikumar, Potential Therapeutic Effects of Curcumin, the Anti-inflammatory Agent, against Neurodegenerative, Cardiovascular, Pulmonary, Metabolic, Autoimmune and Neoplastic Diseases, Int. J. Biochem. Cel Biol, doi:10.1016/j.biocel.2008.06.010
Anand, Kunnumakkara, Newman, Aggarwal, Bioavailability of Curcumin: Problems and Promises, Mol. Pharmaceutics, doi:10.1021/mp700113r
Biswas, Rahman, Modulation of Steroid Activity in Chronic Inflammation: a Novel Anti-inflammatory Role for Curcumin, Mol. Nutr. Food Res, doi:10.1002/mnfr.200700259
Conti, Caraffa, Gallenga, Ross, Kritas et al., IL-1 Induces Throboxane-A2 (TxA2) in COVID-19 Causing Inflammation and Micro-thrombi: Inhibitory Effect of the IL-1 Receptor Antagonist
Curcumin, Thrombosis, and Coagulation, J. Cel Physiol, doi:10.1002/jcp.26249
De Almeida Alvarenga, Leal, Borges, Silva De Aguiar, Faxén-Irving et al., Curcumin -A Promising Nutritional Strategy for Chronic Kidney Disease Patients, J. Funct. Foods, doi:10.1016/j.jff.2017.12.015
Ghosh, Gehr, Ghosh, Curcumin and Chronic Kidney Disease (CKD): Major Mode of Action through Stimulating Endogenous Intestinal Alkaline Phosphatase, Molecules, doi:10.3390/molecules191220139
Gupta, Patchva, Aggarwal, Therapeutic Roles of Curcumin: Lessons Learned from Clinical Trials, Aaps J, doi:10.1208/s12248-012-9432-8
Han, The Effects of Black Pepper on the Intestinal Absorption and Hepatic Metabolism of Drugs, Expert Opin. Drug Metab. Toxicol, doi:10.1517/17425255.2011.570332
Hewlings, Kalman, Curcumin: A Review of its Effects on Human Health, Foods, doi:10.3390/foods6100092
Huang, Wang, Li, Ren, Zhao et al., Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China, The Lancet, doi:10.1016/S0140-6736(20)30183-5
Keihanian, Saeidinia, Bagheri, Johnston, Sahebkar, None
Kim, Ku, Bae, Anticoagulant Activities of Curcumin and its Derivative, BMB Rep, doi:10.5483/bmbrep.2012.45.4.221
Leong, The Spice for Hypertension: Protective Role of Curcuma Longa, Biomed. Pharmacol. J, doi:10.13005/bpj/1555
Liu, Ying, The Inhibitory Effect of Curcumin on Virus-Induced Cytokine Storm and its Potential Use in the Associated Severe Pneumonia, Front Cel Dev Biol, doi:10.3389/fcell.2020.00479
Loeber, Buechner, Dissertatio Inauguralis Medica de Curcuma Officinarum Ejusque Genuinis Virtutibus
Maurya, Kumar, Prasad, Bhatt, Saxena, Structure-based Drug Designing for Potential Antiviral Activity of Selected Natural Products from Ayurveda against SARS-CoV-2 Spike Glycoprotein and its Cellular Receptor, VirusDis, doi:10.1007/s13337-020-00598-8
Mollazadeh, Cicero, Blesso, Pirro, Majeed et al., Immune Modulation by Curcumin: The Role of Interleukin-10, Crit. Rev. Food Sci. Nutr, doi:10.1080/10408398.2017.1358139
Moriyuki, Sekiguchi, Matsubara, Nishikawa, Kawabata, Curcumin Inhibits the Proteinase-Activated Receptor-2-Triggered Prostaglandin E2 Production by Suppressing Cyclooxygenase-2 Upregulation and Akt-dependent Activation of Nuclear Factor-Κb in Human Lung Epithelial Cells, J. Pharmacol. Sci, doi:10.1254/jphs.10126sc
Oppenheimer, Turmeric (Curcumin) in Biliary Diseases, The Lancet, doi:10.1016/s0140-6736(00)98193-5
Ovbiagele, Potential Role of Curcumin in Stroke Prevention, Expert Rev. Neurotherapeutics, doi:10.1586/14737175.8.8.1175
Poolsup, Suksomboon, Kurnianta, Deawjaroen, Effects of Curcumin on Glycemic Control and Lipid Profile in Prediabetes and Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis, PloS one, doi:10.1371/journal.pone.0215840
Ravindran, Prasad, Aggarwal, Curcumin and Cancer Cells: How many Ways Can Curry Kill Tumor Cells Selectively?, AAPS J, doi:10.1208/s12248-009-9128-x
Salehi, Stojanović-Radić, Matejić, Sharifi-Rad, Anil Kumar et al., The Therapeutic Potential of Curcumin: A Review of Clinical Trials, Eur. J. Med. Chem, doi:10.1016/j.ejmech.2018.12.016
Shanmugam, Rane, Kanchi, Arfuso, Chinnathambi et al., The Multifaceted Role of Curcumin in Cancer Prevention and Treatment, Molecules, doi:10.3390/molecules20022728
Sharma, Chopra, Kulkarni, Agrewala, Resveratrol and Curcumin Suppress Immune Response through CD28/CTLA-4 and CD80 Costimulatory Pathway, Clin. Exp. Immunol, doi:10.1111/j.1365-2249.2006.03257.x
Sharma, Nehru, Munshi, Jyothy, Antioxidant Potential of Curcumin against Oxidative Insult Induced by Pentylenetetrazol in Epileptic Rats, Methods Find Exp. Clin. Pharmacol, doi:10.1358/mf.2010.32.4.1452090
Shoba, Joy, Joseph, Majeed, Rajendran et al., Influence of Piperine on the Pharmacokinetics of Curcumin in Animals and Human Volunteers, Planta Med, doi:10.1055/s-2006-957450
Singh, Potential Role of Curcumin against Viral Infections with a View on Structure and Pathogenesis of COVID-19, AIJR Preprints, doi:10.21467/preprints.213
Suresh, Curcumin and Coagulopathy in the COVID19 Era, Ind. J. Clin. Biochem, doi:10.1007/s12291-020-00914-5
Suresh, Srinivasan, Tissue Distribution & Elimination of Capsaicin, Piperine & Curcumin Following Oral Intake in Rats, Indian J. Med. Res
Toden, Goel, The Holy Grail of Curcumin and its Efficacy in Various Diseases: Is Bioavailability Truly a Big Concern?, J Restorat Med, doi:10.14200/jrm.2017.6.0101
Venkatesan, Punithavathi, Babu, Protection from Acute and Chronic Lung Diseases by Curcumin, Adv. Exp. Med. Biol, doi:10.1007/978-0-387-46401-5_17
Vogel, Pelletier, Examen chimique de la racine de Curcuma, J. Pharm
Wongcharoen, Phrommintikul, The Protective Role of Curcumin in Cardiovascular Diseases, Int. J. Cardiol, doi:10.1016/j.ijcard.2009.01.073
Zahedipour, Hosseini, Sathyapalan, Majeed, Jamialahmadi et al., Potential Effects of Curcumin in the Treatment of COVID -19 Infection, Phytotherapy Res, doi:10.1002/ptr.6738
Zhang, -W, Fu, Gao, Liu, Curcumin and Diabetes: a Systematic Review. Evidence-Based Complement, Altern. Med, doi:10.1155/2013/636053
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit